This Month in Psychopharmacology

FDA Approves Liquid Non-Stimulant ADHD Medication

The US FDA has approved once-daily clonidine hydrochloride extended...

Read More

Stimulants and Sleep Difficulties in Pediatric ADHD

A recent comprehensive study delved into the long-term effects of m...

Read More

ADHD Pharmacotherapy and Mortality in Individuals With ADHD

A recent study explored whether initiation of ADHD pharmacotherapy ...

Read More

Why Medical Evaluation Should Be a Part of ADHD Assessment

Not all patients presenting with attentional/cognitive deficits and...

Read More

ADHD Medications and Long-Term Risk of Cardiovascular Diseases: New Data

This recently published case-control study explores the potential c...

Read More

A Potential New Non-Stimulant Treatment Option For ADHD

Encouraging outcomes from two Phase 3 clinical trials assessing the...

Read More

Highlights from 2023 NEI Congress: Sessions on ADHD

Attention deficit hyperactivity disorder (ADHD) is a common neurode...

Read More

ADHD as a Risk Factor For Being Involved in Intimate Partner Violence

In this systematic review and meta-analysis of 14 studies including...

Read More

FDA Approves Multiple Generics of ADHD and BED Treatment

The U.S. Food and Drug Administration has approved several first g...

Read More

Childhood Adversity and the Cortisol Awakening Response in Depression

The hypothalamic pituitary adrenal (HPA) axis is the main regulator...

Read More

Stimulant Treatment in Youth Not Associated With Substance Use Later in Life

Childhood attention-deficit/hyperactivity disorder (ADHD) is linked...

Read More

Long-Term Safety of Methylphenidate in Children and Adolescents with ADHD

Methylphenidate (MPH) is the most frequently prescribed treatment f...

Read More